Ocugen Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;'>OCG</div>
OCGN -- USA Stock  

USD 2.18  0.07  3.11%

As many of us are excited about healthcare space, it is fair to outline Ocugen Inc. We will evaluate why recent Ocugen price moves suggest a bounce in February. What is the firm valuation so far in 2021? We are going to cover Ocugen Inc perspective on valuation to give investors a better transparency on taking a position in it.
Published over two weeks ago
View all stories for Ocugen | View All Stories
Is Ocugen (NASDAQ:OCGN) ready for a correction?
The company currently holds 3.38 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest Ocugen is not taking enough advantage from borrowing. Ocugen Inc has a current ratio of 4.68, suggesting that it is liquid enough and is able to pay its financial obligations when due. Ocugen holds a performance score of 13 on a scale of zero to a hundred. The company holds a Beta of -0.0828, which implies not very significant fluctuations relative to the market. Let's try to break down what Ocugen's beta means in this case. As returns on the market increase, returns on owning Ocugen are expected to decrease at a much lower rate. During the bear market, Ocugen is likely to outperform the market. Although it is essential to pay attention to Ocugen Inc current trending patterns, it is also good to be reasonable about what you can do with equity existing price patterns. Our philosophy towards forecasting future potential of any stock is to look not only at its past charts but also at the business as a whole, including all available fundamental and technical indicators. To evaluate if Ocugen Inc expected return of 7.05 will be sustainable into the future, we have found twenty-seven different technical indicators, which can help you to check if the expected returns are sustainable. Use Ocugen downside variance, as well as the relationship between the accumulation distribution and price action indicator to analyze future returns on Ocugen.
We determine the current worth of Ocugen Inc using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Ocugen Inc based exclusively on its fundamental and basic technical indicators. By analyzing Ocugen's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Ocugen's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Ocugen. We calculate exposure to Ocugen's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Ocugen's related companies.

Ocugen Inc Investment Alerts

Ocugen investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Ocugen Inc performance across your portfolios.Please check all investment alerts for Ocugen

Ocugen Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Ocugen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ocugen competition to find correlations between indicators driving the intrinsic value of Ocugen.

How Ocugen utilizes its cash?

To perform a cash flow analysis of Ocugen, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Ocugen is receiving and how much cash it distributes out in a given period. The Ocugen cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Ocugen Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (16.4 Million)

Acquisition by Tammara Vijay of 220500 shares of Ocugen subject to Rule 16b-3

Legal trades by Ocugen insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Ocugen insider trading alert for grant of option (right to buy) by Tammara Vijay, Senior Vice President, on 4th of January 2021. This event was filed by Ocugen Inc with SEC on 2021-01-04. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Ocugen Investor Appetite?

The latest price rise of Ocugen Inc may encourage institutional investors to take a closer look at the company as it is trading at a share price of 3.13 on 97,059,900 in trading volume. The company executives may have good odds in positioning the company resources to exploit market volatility in February. The stock standard deviation of daily returns for 30 days investing horizon is currently 37.45. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Ocugen partners.
 2010 2020 2021 (projected)
Sales per Share5.985.385.35
Return on Sales138.58124.72123.99


Ocugen Earnings Before Interest Taxes and Depreciation Amortization EBITDA is quite stable at the moment. Further, Ocugen Average Assets is decreasing over the last 8 years. The latest value of Ocugen Average Assets is 18,102,603. Ocugen Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 8 years. The previous year's value of Ocugen Earnings Before Interest Taxes and Depreciation Amortization EBITDA was -22,537,483. Further, Ocugen Average Assets is decreasing over the last 8 years. The latest value of Ocugen Average Assets is 18,102,603.

Ocugen implied volatility may change after the rise

Latest coefficient of variation is at 627.1. Ocugen Inc is displaying above-average volatility over the selected time horizon. Investors should scrutinize Ocugen Inc independently to ensure intended market timing strategies are aligned with expectations about Ocugen volatility.

The Bottom Line

Whereas some other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Ocugen may offer a potential longer-term growth to institutional investors. To conclude, as of the 4th of January 2021, our up-to-date 30 days advice on the company is Strong Sell. We believe Ocugen is currently overvalued with low probability of financial unrest for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Ocugen Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com